Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
October 30, 2024 5:04 PM 4 min read

A Look Ahead: Teleflex's Earnings Forecast

by Benzinga Insights Benzinga Staff Writer
Follow

Teleflex (NYSE:TFX) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Teleflex will report an earnings per share (EPS) of $3.39.

Investors in Teleflex are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Overview of Past Earnings

The company's EPS beat by $0.09 in the last quarter, leading to a 0.5% increase in the share price on the following day.

Here's a look at Teleflex's past performance and the resulting price change:

Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023
EPS Estimate 3.33 3.07 3.26 3.27
EPS Actual 3.42 3.21 3.38 3.64
Price Change % 1.0% 2.0% 0.0% 1.0%

Analyst Opinions on Teleflex

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Teleflex.

The consensus rating for Teleflex is Outperform, based on 6 analyst ratings. With an average one-year price target of $264.5, there's a potential 11.87% upside.

Understanding Analyst Ratings Among Peers

In this comparison, we explore the analyst ratings and average 1-year price targets of Globus Medical, Penumbra and Glaukos, three prominent industry players, offering insights into their relative performance expectations and market positioning.

Peers Comparative Analysis Summary

The peer analysis summary provides a snapshot of key metrics for Globus Medical, Penumbra and Glaukos, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

Key Takeaway:

Teleflex ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.

Discovering Teleflex: A Closer Look

Teleflex's Financial Performance

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of 0.87% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Teleflex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.68%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Teleflex's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.77%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Teleflex's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.07%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 0.4, Teleflex adopts a prudent financial strategy, indicating a balanced approach to debt management.

To track all earnings releases for Teleflex visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
EarningsBZI-EP
TFX Logo
TFXTeleflex Inc
$103.75-%
Overview
  • As per analysts' assessments, Globus Medical is favoring an Outperform trajectory, with an average 1-year price target of $80.43, suggesting a potential 65.98% downside.
  • The prevailing sentiment among analysts is an Buy trajectory for Penumbra, with an average 1-year price target of $230.67, implying a potential 2.44% downside.
  • The prevailing sentiment among analysts is an Buy trajectory for Glaukos, with an average 1-year price target of $141.86, implying a potential 40.0% downside.
Company Consensus Revenue Growth Gross Profit Return on Equity
Teleflex Outperform 0.87% $416.46M 1.77%
Globus Medical Outperform 115.93% $369.65M 0.80%
Penumbra Buy 14.49% $162.83M -5.09%
Glaukos Buy 19.02% $73.14M -9.06%

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

TFX Logo
TFXTeleflex Inc
$103.75-%
Overview
Comments
Loading...